Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
Recruiting · NCT07690436 · Observational (researchers observe without assigning treatment) · Lead sponsor: AstraZeneca
View the official record on ClinicalTrials.gov →What this trial is about
This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and preliminarily evaluating a machine learning model to discriminate ATTR-CM cases from HF controls without ATTR-CM.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- 1\. Participant must be 18 years and older at the time of signing the informed consent form.
- 2\. Participants with either of the following:
- \- Positive ATTR-CM cases: Participants with a clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) with amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining, or DPD-Tc, PYP-Tc, or HMDP-Tc scintigraphy with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio.
- \- Control population: Participants with a clinical diagnosis of guideline-directed medical therapy-directed heart failure (HF) and either:
- a) Subgroup A: Definitively excluded ATTR-CM amyloidosis: negative cardiac or non-cardiac tissue biopsy for amyloid, or negative technetium scintigraphy within the past 2 years.
- b) Subgroup B: Low probability of ATTR-CM amyloidosis, not definitively excluded: absence of amyloid-suggestive features on echocardiography (ECHO), electrocardiography (ECG), or cardiac magnetic resonance imaging (MRI) within the past 2 years, with documented clinical assessment indicating HF etiology unlikely attributable to amyloidosis; no amyloid-specific testing (technetium scintigraphy or biopsy) performed.
- 3\. Participant or legally authorized representative (LAR) must sign the informed consent form.
Exclusion criteria
- 1\. Any known eye condition that may preclude clear imaging of the retina.
- 2\. Any known history of amyloid light-chain (AL) amyloidosis.
- 3\. Any ocular surgery that, in the opinion of the investigator, makes participation in the study undesirable.
- 4\. Any medical condition that, in the opinion of the investigator, makes participation in the study undesirable, for example, if the participant is critically unwell or requires ongoing emergency treatment.
- 5\. Involvement in the planning and/or conduct of the study.
- 6\. In the opinion of the investigator, the participant is unlikely to comply with study procedures, restrictions, and requirements.
- 7\. Previous enrollment in the present study.
Where it is running
20 locations listed across 6 US states.
- Research Site - Palo Alto, California, United States
- Research Site - Jacksonville, Florida, United States
- Research Site - Chicago, Illinois, United States
- Research Site - Boston, Massachusetts, United States
- Research Site - Portland, Oregon, United States
- Research Site - Germantown, Tennessee, United States
- Research Site - Berlin, Germany
- Research Site - Essen, Germany
- Research Site - Frankfurt am Main, Germany
- Research Site - Gothenburg, Sweden
- Research Site - Guimarães, Portugal
- Research Site - L'Hospitalet de Llobregat, Spain
- Research Site - Lisbon, Portugal
- Research Site - Lisbon, Portugal
- Research Site - Lisbon, Portugal
- Research Site - Madrid, Spain
- Research Site - Palma de Mallorca, Spain
- Research Site - Solna, Sweden
- Research Site - Vasterbottens Lan, Sweden
- Research Site - Würzburg, Germany